Nexus Surgical

Why is Nexus Surgical and Medicare Ltd falling/rising?

As of 27-Aug, Nexus Surgical and Medicare Ltd's stock price has risen to 22.43, reflecting a 2.65% increase, supported by strong performance metrics including a 28.17% year-to-date gain and a 137.35% increase over three years, significantly outperforming the Sensex. Increased investor participation and positive technical indicators further bolster confidence in the stock.

As of 27-Aug, Nexus Surgical and Medicare Ltd is experiencing a rise in its stock price, currently at 22.43, with a change of 0.58, reflecting an increase of 2.65%. This upward movement is supported by several factors. Over the past week, the stock has surged by 23.31%, significantly outperforming the Sensex, which has declined by 0.78%. Additionally, the stock has shown strong performance over the past month with an 18.05% increase compared to a slight gain of 0.13% in the Sensex.<BR><BR>Year-to-date, Nexus Surgical has achieved a remarkable 28.17% increase, while the Sensex has fallen by 9.72%. Over the past year, the stock has risen by 24.20%, contrasting with the Sensex's decline of 4.77%. The three-year performance is particularly impressive, with a 137.35% increase for Nexus Surgical compared to an 18.57% rise in the Sensex.<BR><BR>Today's performance indicates that the stock has outperformed its sector by 4.6% and has been on a consecutive gain streak for the last two days, accumulating a total return of 24.66% in this period. Furthermore, Nexus Surgical is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is a positive technical indicator.<BR><BR>Investor participation has also increased, with a delivery volume of 19.56k on August 26, marking a substantial rise of 780.92% against the 5-day average delivery volume. This increase in trading activity suggests heightened interest and confidence among investors. Overall, these factors contribute to the rising stock price of Nexus Surgical and Medicare Ltd.

Which are the latest news on Nexus Surgical?

Should I buy, sell or hold Nexus Surgical and Medicare Ltd?

Who are in the management team of Nexus Surgical?

The management team of Nexus Surgical includes Ram Swaroop Mahadev Joshi (Whole Time Director & CFO), Pawan Choudhary (Executive Director), and independent non-executive directors Rajesh Sodhani, Avinash Kumar Ardawatia, and Neha Kailash Bhageria.

The management team of Nexus Surgical includes the following individuals:<BR><BR>1. **Ram Swaroop Mahadev Joshi** - Whole Time Director & CFO<BR>2. **Pawan Choudhary** - Executive Director<BR>3. **Rajesh Sodhani** - Independent Non-Executive Director<BR>4. **Avinash Kumar Ardawatia** - Independent Non-Executive Director<BR>5. **Neha Kailash Bhageria** - Independent Non-Executive Director<BR><BR>If you need more specific information about their roles or contributions, feel free to ask!

What does Nexus Surgical do?

Nexus Surgical and Medicare Ltd trades medical essentials and operates as a Micro Cap in the NBFC industry. As of June 2026, it reported net sales of 3 Cr and a market cap of INR 10 Cr.

Overview: <BR>Nexus Surgical and Medicare Ltd is engaged in the trading of medical essentials and operates within the Non Banking Financial Company (NBFC) industry, categorized as a Micro Cap.<BR><BR>History: <BR>The company was incorporated in 1992 and was formerly known as Nexus Commodities and Technologies Ltd. It has undergone a status change and is currently focused on trading medical essentials. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 10 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 14.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 40.56% <BR>Price to Book: 5.52 <BR><BR>Contact Details: <BR>Address: Gala No 4 Saarthak Bldg No 1, Square Industrial Park Palghar Maharashtra : 401208 <BR>Email: nexuscom99@gmail.com <BR>Website: http://www.nexusmed.co.in

Who are the peers of the Nexus Surgical?

Nexus Surgical's peers include Yunik Managing, Kuber Udyog, Octal Credit Cap, Libord Securitie, Adcon Capital, Rajputana Invest, and Sharp Investment. Kuber Udyog leads in 1-year returns at 95.27%, while Nexus Surgical has a return of 0.64%.

Peers: The peers of Nexus Surgical are Yunik Managing, Kuber Udyog, Octal Credit Cap, Libord Securitie, Adcon Capital, Rajputana Invest, and Sharp Investment.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kuber Udyog, Octal Credit Cap, Adcon Capital, and Rajputana Invest, while Average management risk is found at Nexus Surgical. Below Average management risk is present at Yunik Managing and Sharp Investment, and the rest. Growth is Average at Kuber Udyog, Adcon Capital, and Rajputana Invest, while Nexus Surgical also has Average growth. Below Average growth is noted at Yunik Managing, Octal Credit Cap, and the rest, while Libord Securitie and Sharp Investment do not qualify. Excellent capital structure is seen at Kuber Udyog, Octal Credit Cap, Adcon Capital, Nexus Surgical, and Rajputana Invest, while Below Average capital structure is present at Yunik Managing and the rest.<BR><BR>Return Snapshot: Kuber Udyog has the highest 1-year return at 95.27%, while Sharp Investment has the lowest at -38.71%. Nexus Surgical's 1-year return is 0.64%, which is significantly lower than Kuber Udyog's but higher than Sharp Investment's. Additionally, peers with negative six-month returns include Yunik Managing, Octal Credit Cap, Adcon Capital, Rajputana Invest, and Sharp Investment.

How big is Nexus Surgical?

As of 14th August, Nexus Surgical and Medicare Ltd has a market capitalization of 10.67 Cr, with recent net sales of 8.70 Cr and net profit of 0.78 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Nexus Surgical and Medicare Ltd has a market capitalization of 10.67 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 8.70 Cr, while the sum of Net Profit for the same period is 0.78 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 1.06 Cr, and Total Assets amount to 2.27 Cr.

Are Nexus Surgical and Medicare Ltd latest results good or bad?

Nexus Surgical's latest results show strong profitability with a net profit increase of 41.18% quarter-over-quarter, but a concerning 30.03% decline in net sales raises questions about revenue stability. Investors should be cautious and monitor the company's ability to stabilize its revenue streams.

Nexus Surgical's latest results present a mixed picture. On one hand, the company achieved a net profit of ₹0.24 crores in Q4 FY26, which is a significant improvement of 41.18% compared to the previous quarter and a remarkable 166.67% increase year-on-year. This indicates strong profitability growth and improved operational efficiency, as evidenced by a PAT margin that rose to 11.71%.<BR><BR>However, the net sales for the same quarter saw a substantial decline of 30.03% compared to the previous quarter, dropping to ₹2.05 crores. While this represents a year-on-year increase of 38.51%, the sequential drop highlights volatility in revenue generation, which is a concern for the company's stability.<BR><BR>Overall, while the profitability metrics are encouraging, the erratic nature of revenue growth raises questions about the sustainability of this performance. Investors should be cautious and monitor whether the company can stabilize its revenue streams moving forward.

When is the next results date for Nexus Surgical and Medicare Ltd?

The next results date for Nexus Surgical and Medicare Ltd is 14 February 2026.

The next results date for Nexus Surgical and Medicare Ltd is scheduled for 14 February 2026.

How has been the historical performance of Nexus Surgical?

Nexus Surgical has shown significant growth in net sales and profitability, with net sales increasing from 1.55 Cr in March 2023 to 5.72 Cr in March 2025, and profit after tax rising from 0.17 Cr to 0.50 Cr, while maintaining zero debt. The company's operating profit margin improved, reflecting a positive financial trajectory overall.

Answer:<BR>The historical performance of Nexus Surgical shows a significant upward trend in net sales and profitability over the past few years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Nexus Surgical's net sales have increased from 1.55 Cr in March 2023 to 5.72 Cr in March 2025, indicating strong growth. Total operating income followed a similar trend, rising from 1.55 Cr in March 2023 to 5.72 Cr in March 2025. The company's total expenditure also grew, reaching 5.06 Cr in March 2025, up from 1.34 Cr in March 2023. Despite this increase, the operating profit (PBDIT) improved from 0.21 Cr in March 2023 to 0.67 Cr in March 2025, reflecting a healthier operating profit margin of 11.54% in March 2025 compared to 13.55% in March 2023. Profit before tax also rose from 0.23 Cr in March 2023 to 0.67 Cr in March 2025, with profit after tax increasing from 0.17 Cr to 0.50 Cr over the same period. The earnings per share (EPS) improved significantly from 0.31 in March 2023 to 0.91 in March 2025. On the balance sheet, total assets increased from 0.91 Cr in March 2023 to 2.27 Cr in March 2025, while total liabilities rose from 0.91 Cr to 2.27 Cr in the same timeframe. The company has maintained zero debt throughout this period. Overall, Nexus Surgical's financial performance demonstrates a positive trajectory in sales, profitability, and asset growth.

Who are the top shareholders of the Nexus Surgical?

The top shareholders of Nexus Surgical are Mildred Mercantile Private Limited with 18.55%, Harivardhan Steel & Alloys Private Limited at 16.01%, and individual investors holding a combined 44.64%. There are no institutional holdings in the company.

The top shareholders of Nexus Surgical include Mildred Mercantile Private Limited, which holds the highest promoter stake at 18.55%. The next significant public shareholder is Harivardhan Steel & Alloys Private Limited, with a holding of 16.01%. Additionally, individual investors collectively hold 44.64% of the company's shares. There are no institutional holdings reported, as mutual funds and foreign institutional investors do not hold any shares in Nexus Surgical.

Is Nexus Surgical overvalued or undervalued?

As of November 15, 2023, Nexus Surgical is considered very expensive and overvalued with a PE ratio of 9.23, an EV to EBIT ratio of 8.90, and a high ROE of 47.17%, but it has underperformed the Sensex by 37.39% year-to-date.

As of 15 November 2023, Nexus Surgical's valuation grade has moved from risky to very expensive, indicating a significant shift in its market perception. The company is currently deemed overvalued. Key ratios include a PE ratio of 9.23, an EV to EBIT ratio of 8.90, and a ROE of 47.17%. These figures suggest that while the company has a high return on equity, its valuation metrics are not compelling when compared to peers.<BR><BR>In comparison to its industry peers, Nexus Surgical's PE ratio of 9.23 is lower than Life Insurance's PE of 12.54, but significantly higher than Bajaj Finance's PE of 35.01, which is categorized as very expensive. The PEG ratio of 0.07 also highlights that the stock may not be justified at its current price given its growth prospects. Additionally, Nexus Surgical has underperformed the Sensex over various time frames, particularly year-to-date, where it has declined by 37.39% compared to the Sensex's gain of 5.59%.

What is the technical trend for Nexus Surgical?

As of June 4, 2025, Nexus Surgical's trend is mildly bearish due to daily moving averages, despite mixed signals from weekly and monthly indicators, with the stock down 6.39% over the past week.

As of 4 June 2025, the technical trend for Nexus Surgical has changed from sideways to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend. The weekly MACD and KST are mildly bullish, but the monthly MACD and KST are mildly bearish, suggesting mixed signals across different time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, but this is overshadowed by the bearish daily moving averages. Overall, the strength of the bearish trend is supported by the recent price action, with the stock down 6.39% over the past week, contrasting with a positive return from the Sensex.

Has Nexus Surgical declared dividend?

No Dividend History Available